financetom
Business
financetom
/
Business
/
FirstEnergy misses quarterly profit estimates, narrows forecast
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FirstEnergy misses quarterly profit estimates, narrows forecast
Nov 3, 2024 2:32 PM

Oct 29 (Reuters) - Utility firm FirstEnergy ( FE )

missed third-quarter profit estimates on Tuesday, hurt by higher

storm restoration expenses and lower tax benefits.

About 578,000 of FirstEnergy's ( FE ) customers were left without

power in August after severe storms swept across northeast Ohio,

Pennsylvania and New Jersey, causing hundreds of broken poles

and crossarms.

The company's total quarterly operating expenses rose 6.4%

to $3 billion from a year earlier.

The company said its earnings were also impacted by dilution

related to the sale of the 30% stake in FirstEnergy

Transmission, which was sold to Brookfield Super-Core

Infrastructure Partners in an all-cash deal of $3.5 billion.

FirstEnergy's ( FE ) electric distribution companies serve 6

million customers in Ohio, Pennsylvania, New Jersey, West

Virginia, Maryland and New York.

The Akron, Ohio-based firm narrowed its current-year

adjusted earnings forecast to between $2.61 and $2.71 per share,

from $2.61 to $2.81, reflecting lower customer demand from mild

weather, lower distribution revenues in Ohio and higher storm

restoration costs in the third quarter.

The company reported an adjusted profit of 85 cents per

share for the quarter ended Sept. 30, compared with analysts'

average estimate of 90 cents, according to LSEG.

The utility firm also increased its current-year capital

investment plan by $300 million to $4.6 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Perpetua Resources Signs Agreement to Explore Antimony Processing in Idaho
Update: Perpetua Resources Signs Agreement to Explore Antimony Processing in Idaho
Dec 9, 2024
11:09 AM EST, 12/09/2024 (MT Newswires) -- (Adds analyst comment; updates shares.) Perpetua Resources ( PPTA ) said Monday it agreed to explore antimony processing opportunities in Idaho with Sunshine Silver Mining & Refining. Under the terms of the agreement, the companies will evaluate the technical potential for processing and refining antimony from Perpetua's Stibnite gold project in Idaho at...
China's BYD to focus on plug-in hybrid cars in European expansion
China's BYD to focus on plug-in hybrid cars in European expansion
Dec 9, 2024
MILAN, Dec 9 (Reuters) - Hybrid technology will be key for the European expansion of Chinese EV giant BYD amid soft demand for fully-electric vehicles, the special adviser in the region for the manufacturer said on Monday. BYD, China's top electric vehicle producer, entered Europe's passenger car market in 2022. It has an aggressive product roll-out plan for next year,...
Market Chatter: Former ASML Employee Reportedly Accused of Selling Chip Trade Secrets to Russia
Market Chatter: Former ASML Employee Reportedly Accused of Selling Chip Trade Secrets to Russia
Dec 9, 2024
11:07 AM EST, 12/09/2024 (MT Newswires) -- A former ASML (ASML) employee has been accused by the Dutch government of selling the semiconductor equipment manufacturer's trade secrets to Russian companies in violation of international sanctions, Bloomberg reported Monday. The 43-year-old man originally from Russia was charged during a court hearing Monday in Rotterdam, according to the report. The suspect allegedly...
GSK's Blenrep Combination Therapy for Multiple Myeloma Gets Priority Review in China
GSK's Blenrep Combination Therapy for Multiple Myeloma Gets Priority Review in China
Dec 9, 2024
11:09 AM EST, 12/09/2024 (MT Newswires) -- GSK (GSK) said Monday its Blenrep, in combination with bortezomib plus dexamethasone, as a therapy for relapsed or refractory multiple myeloma has been accepted for priority review in China. The National Medical Products Administration's acceptance marks the seventh major regulatory filing for Blenrep this year, GSK said. In a filing to the US...
Copyright 2023-2026 - www.financetom.com All Rights Reserved